Using PD-1 blockade to enhance CAR T-cell efficacy in R/R LBCL

Lixia Sheng, MD, The First Affiliated Hospital of Ningbo University, Ningbo, China, comments on the potential of combining PD-1 blockade with CAR T-cell therapy in relapsed/refractory (R/R) large B-cell lymphoma (LBCL) to combat immune exhaustion and enhance CAR-T efficacy. In a Phase I trial (NCT05659628), CD19 CAR T-cells expressing IL-7 and CCL19 were combined with the anti-PD-1 antibody tislelizumab in this patient population. The approach demonstrated promising efficacy, even in patients with high PD-L1 expression at baseline. This interview took place at the 51st Annual Meeting of the EBMT in Florence, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.